Cancers & treatments·Regimen libraryFirst line

CAPTEM

Checked 2026-09-09

Advanced pancreatic neuroendocrine tumour

One cycle

every 28 days

28-day cycle, until progression (E2211 to 13 cycles)Oral Daily oral course

Components

Drug	Dose	Route	Days	Note
Capecitabine	750 mg/m² twice daily	Oral	D1-14
Temozolomide Oral alkylating chemotherapy	200 mg/m²	Oral	D10-14

Cycles

until progression (E2211 to 13 cycles)

28-day cycle

Emetogenicity

Moderate (30-90%)

G-CSF

Not routine

Used in

Neuroendocrine tumours

Products

Capecitabine + temozolomide (CAPTEM)Temozolomide

Source

ECOG-ACRIN E2211, JCO 2023

Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.

Other regimens for these cancers

177Lu-DOTATATE (PRRT)

SSTR-positive gastroenteropancreatic NET after somatostatin analogue

every 56 days × 4

Everolimus

Advanced progressive NET (RADIANT-3, RADIANT-4); RCC and HR-positive breast cancer after prior therapy

every 28 days

Cisplatin + etoposide (EP)

Limited-stage SCLC with concurrent thoracic radiotherapy; stage III NSCLC chemoradiation; high-grade neuroendocrine carcinoma

every 21 days × 4

Sunitinib 4/2

Advanced clear-cell RCC favourable risk or when immunotherapy is contraindicated; imatinib-resistant GIST; pancreatic NET

every 42 days

All regimens 177Lu-DOTATATE (PRRT) →